OmniAb Investor Conference Presentation Deck

Growth of Partner Programs PROGRESSION AND PERFORMANCE IN PROGRAMS BY STAGE OF DEVELOPMENT 21 as of 2016(¹) Preclinical: 1 Discovery: 20 Preclinical: 12 282 as of 09/30/22(²) Phase 1: 18 Phase 2: 2 Substantial progress in all phases, increase in discovery programs expected to feed growth in new clinical programs and future approvals Phase 3: 2 (1) Estimated at the time of acquisition of OMT (2) In August 2022, our partner Jansen received marketing approval in the EU for teclistamab; and in October of 2022, Janssen received accelerated approval for teclistamab by the US FDA Approved: 3 Discovery: 245 15 OmniAb

View entire presentation